文献速递眼底病与葡萄膜炎

视网膜内层结构紊乱与视网膜静脉阻塞性黄斑水肿抗VEGF治疗后视力反应的相关性

Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
PubMed 文献 · JAMA Ophthalmol · 2019-01-01

该回顾性研究纳入147例视网膜静脉阻塞继发黄斑水肿患者,评估基线及抗VEGF治疗后视网膜内层结构紊乱(DRIL)与视力(VA)的关系。结果显示基线DRIL存在及治疗后DRIL负荷变化与ETDRS视力评分改善相关,提示DRIL可能作为视力预后的生物标志物。

要点

  • 基线DRIL见于61.9%的视网膜静脉阻塞继发黄斑水肿患眼。
  • CRVO/HRVO组基线无DRIL与6个月时更佳视力增益相关。
  • BRVO组持续DRIL与6个月内视力增益较少相关。

核心结论

  • 基线DRIL存在及抗VEGF治疗中DRIL负荷变化可能是视网膜静脉阻塞继发黄斑水肿患者ETDRS视力评分改善的有用生物标志物。

研究设计与样本

  • 回顾性研究纳入147例18岁及以上、未治疗过的BRVO、CRVO或HRVO患者,随访至少12个月,就诊于三级眼科中心。
  • 两名设盲评估者基于基线、6个月和12个月SD-OCT上3个预定区域的DRIL存在情况计算DRIL评分,分歧由第三名设盲评估者裁定。

临床怎么用

  • 对于视网膜静脉阻塞继发黄斑水肿患者,基线及抗VEGF治疗过程中的DRIL评估可能有助于预测视力预后。

局限性

  • 本研究为回顾性设计,样本来自单一三级眼科中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Disorganization of retinal inner layers (DRIL) has demonstrated significant correlations with visual acuity (VA) in center-involved diabetic macular edema. In patients with retinal vein occlusion (RVO) and secondary macular edema, DRIL may be a useful biomarker in determining VA outcomes. OBJECTIVE: To examine whether DRIL at baseline and after treatment is associated with VA in RVO. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of records of 147 patients 18 years or older with treatment-naive branch RVO (BRVO), central RVO (CRVO), or hemispheric RVO (HRVO), with a minimum of 12 months of follow-up, who presented to a tertiary ophthalmic center from December 1, 2010, to January 1, 2016, was conducted. Data collection continued through January 2017. Exclusion criteria included active confounding retinal or ocular disease, history of pars plana vitrectomy, or prior intravitreal injections. Two masked graders calculated a DRIL score based on DRIL presence in 3 predefined regions on spectral-domain optical coherence tomography at baseline, 6 months, and 12 months. A third masked grader was used for discrepancies. EXPOSURES: Anti-vascular endothelial growth factor (AVF) therapy (ranibizumab, aflibercept, or bevacizumab) determined by the treating physician. MAIN OUTCOMES AND MEASURES: The DRIL score at baseline for determining VA outcomes and correlation of VA with changes in DRIL burden in response to AVF therapy. RESULTS: In the 147 patients (mean [SD] age, 68.9 [13.1] years; 75 [51.0%] female), baseline DRIL was seen in 91 eyes (61.9%). In the BRVO group but not the CRVO group, baseline DRIL was associated with lower baseline Early Treatment Diabetic Retinopathy Study (ETDRS) score (score of 66.7 for no DRIL vs 54.6 for DRIL, P = .002). Absence of DRIL at baseline in the CRVO/HRVO group correlated with greater VA gains at 6 months, adjusting for baseline VA (score change of 19.50 for no DRIL vs 12.72 for DRIL; P = .04). During 12 months, continued DRIL presence in BRVO was associated with less VA gain up to 6 months (score change of 6.2 for the DRIL increase group vs 18.6 for the DRIL decrease group vs 2.9 for the DRIL stable group; P = .02). Increasing DRIL scores in CRVO/HRVO were associated with reduced VA improvement at 6 months (score change of -0.12 for the DRIL increase group vs 16.90 for the DRIL decrease group vs 8.45 for the DRIL stable group; P = .002) and 12 months (score change of -1.91 for the DRIL increase group vs 17.83 for the DRIL decrease group vs 6.97 for the DRIL stable group; P < .001). CONCLUSIONS AND RELEVANCE: Baseline DRIL presence and DRIL burden changes with AVF therapy for macular edema secondary to RVO may be useful biomarkers of ETDRS score improvements.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Babiuch AS, Han M, Conti FF, et al. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion. JAMA Ophthalmol. 2019. PMID: 30286219. doi:10.1001/jamaophthalmol.2018.4484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。